Gsk (GSK) Long-Term Deferred Tax (2016 - 2025)
Historic Long-Term Deferred Tax for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $8.3 billion.
- Gsk's Long-Term Deferred Tax rose 184.73% to $8.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 billion, marking a year-over-year increase of 184.73%. This contributed to the annual value of $8.6 billion for FY2024, which is 1479.85% up from last year.
- Per Gsk's latest filing, its Long-Term Deferred Tax stood at $8.3 billion for Q3 2025, which was up 184.73% from $8.8 billion recorded in Q2 2025.
- Over the past 5 years, Gsk's Long-Term Deferred Tax peaked at $8.8 billion during Q2 2025, and registered a low of $421.3 million during Q1 2022.
- Its 5-year average for Long-Term Deferred Tax is $6.9 billion, with a median of $7.1 billion in 2023.
- Its Long-Term Deferred Tax has fluctuated over the past 5 years, first plummeted by 9291.38% in 2022, then soared by 151842.39% in 2023.
- Over the past 5 years, Gsk's Long-Term Deferred Tax (Quarter) stood at $7.0 billion in 2021, then dropped by 5.65% to $6.6 billion in 2022, then grew by 13.13% to $7.5 billion in 2023, then grew by 15.52% to $8.7 billion in 2024, then decreased by 4.06% to $8.3 billion in 2025.
- Its Long-Term Deferred Tax stands at $8.3 billion for Q3 2025, versus $8.8 billion for Q2 2025 and $8.1 billion for Q1 2025.